February 28, 2013
ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent International AB (OMXS: BINV), announce today the publication of a paper in the prestigious journal
, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children.
publication highlights for the first time a new mechanism of action, showing that PlGF plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma.
The novel positive findings in this paper provide evidence that could warrant further development of TB-403 as one of the first targeted therapies to treat this childhood cancer. TB-403 is a monoclonal antibody against placental growth factor (PlGF). PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels.
TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed by Prof.
at the University of Leuven,
paper is reporting the findings of new pre-clinical research performed at the Massachusetts General Hospital in
, in collaboration with the team of Prof
With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the role of TB-403 for ophthalmic indications.
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company's lead product, JETREA
(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in
, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA
the United States
. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA
ThromboGenics and Alcon intend to share the costs equally of developing JETREA
for a number of new vitreoretinal indications.
The JETREA European Marketing Authorisation Application is currently under review by the European Medicines Agency. Following the positive CHMP recommendation, a final decision by the European Commission on European approval is expected in the first half of 2013.